OTC · MDRX
Healthcare · Medical - Healthcare Information Services
$4.90
Up+$0.30 (+6.41%)
Updated Sep 14, 2026, 7:29 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MDRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MDRX.
MDRX research
Company profile and research snapshot.
VERADIGM INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 31, 2025 | Stephens & Co. | Equal-Weight | — |
| May 28, 2024 | TD Cowen | Buy | — |
| Mar 19, 2024 | Deutsche Bank | Hold | — |
| Jan 19, 2024 | RBC Capital | Outperform | — |
| Jan 3, 2024 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
CHICAGO, September 08, 2026--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that it will now present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15th at 3:35PM CT. A live webcast of the fireside chat will be available at the Veradigm investor relations website.
SeekingAlpha · Feb 18, 2026
businesswire.com · Nov 17, 2025
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced enhancements to the artificial intelligence (AI) enhanced Ambient Scribe solution for Veradigm EHR customers. This milestone reflects Veradigm's commitment to delivering evolved AI solutions that improve clinical documentation, support clinical decision-making, and enhance patient care. Since its launch last year, Veradigm Ambient Scribe has developed into a robus.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDRX.
